Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to rival jabs such as Mounjaro.

Eli Lilly is expected to report robust quarterly sales and profits, outpacing its Danish rival Novo Nordisk. Despite some ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Investors and analysts say they expect Eli Lilly to report stronger ...